Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H] (411/417 = 99%)† (Homo sapiens (Human)) | BDBM279948 (US10028961, Compound 101 | US10172864, Compound 10...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | 6.5 | 25 |
Agios Pharmaceuticals, Inc. US Patent | Assay Description In the primary reaction, the reduction of α-KG acid to 2-HG is accompanied by a concomitant oxidation of NADPH to NADP. The amount of NADPH rema... | US Patent US10028961 (2018) BindingDB Entry DOI: 10.7270/Q2ZW1NXM | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H] (411/417 = 99%)† (Homo sapiens (Human)) | BDBM279977 (US10028961, Compound 130 | US10172864, Compound 13...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | n/a | n/a |
Agios Pharmaceuticals, Inc. US Patent | Assay Description A test compound is prepared as 10 mM stock in DMSO and diluted to 50× final concentration in DMSO, for a 50 μl reaction mixture. IDH enzyme acti... | US Patent US10172864 (2019) BindingDB Entry DOI: 10.7270/Q2ZK5JQ3 | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H] (411/417 = 99%)† (Homo sapiens (Human)) | BDBM279977 (US10028961, Compound 130 | US10172864, Compound 13...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | 6.5 | 25 |
Agios Pharmaceuticals, Inc. US Patent | Assay Description In the primary reaction, the reduction of α-KG acid to 2-HG is accompanied by a concomitant oxidation of NADPH to NADP. The amount of NADPH rema... | US Patent US10028961 (2018) BindingDB Entry DOI: 10.7270/Q2ZW1NXM | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132C] (413/414 > 99%)† (Homo sapiens (Human)) | BDBM279977 (US10028961, Compound 130 | US10172864, Compound 13...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | 6.5 | 25 |
Agios Pharmaceuticals, Inc. US Patent | Assay Description In the primary reaction, the reduction of α-KG acid to 2-HG is accompanied by a concomitant oxidation of NADPH to NADP. The amount of NADPH rema... | US Patent US10028961 (2018) BindingDB Entry DOI: 10.7270/Q2ZW1NXM | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H] (411/417 = 99%)† (Homo sapiens (Human)) | BDBM279948 (US10028961, Compound 101 | US10172864, Compound 10...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | 6.5 | 25 |
Agios Pharmaceuticals, Inc. US Patent | Assay Description In the primary reaction, the reduction of α-KG acid to 2-HG is accompanied by a concomitant oxidation of NADPH to NADP. The amount of NADPH rema... | US Patent US10028961 (2018) BindingDB Entry DOI: 10.7270/Q2ZW1NXM | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H] (411/417 = 99%)† (Homo sapiens (Human)) | BDBM279948 (US10028961, Compound 101 | US10172864, Compound 10...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Agios Pharmaceuticals, Inc. US Patent | Assay Description A test compound is prepared as 10 mM stock in DMSO and diluted to 50× final concentration in DMSO, for a 50 μl reaction mixture. IDH enzyme acti... | US Patent US10028961 (2018) BindingDB Entry DOI: 10.7270/Q2ZW1NXM | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132C] (413/414 > 99%)† (Homo sapiens (Human)) | BDBM279948 (US10028961, Compound 101 | US10172864, Compound 10...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Agios Pharmaceuticals, Inc. US Patent | Assay Description A test compound is prepared as 10 mM stock in DMSO and diluted to 50× final concentration in DMSO, for a 50 μl reaction mixture. IDH enzyme acti... | US Patent US10028961 (2018) BindingDB Entry DOI: 10.7270/Q2ZW1NXM | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H] (411/417 = 99%)† (Homo sapiens (Human)) | BDBM279977 (US10028961, Compound 130 | US10172864, Compound 13...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Agios Pharmaceuticals, Inc. US Patent | Assay Description A test compound is prepared as 10 mM stock in DMSO and diluted to 50× final concentration in DMSO, for a 50 μl reaction mixture. IDH enzyme acti... | US Patent US10028961 (2018) BindingDB Entry DOI: 10.7270/Q2ZW1NXM | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H] (411/417 = 99%)† (Homo sapiens (Human)) | BDBM279948 (US10028961, Compound 101 | US10172864, Compound 10...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | n/a | n/a |
Agios Pharmaceuticals, Inc. US Patent | Assay Description In the primary reaction, the reduction of α-KG acid to 2-HG is accompanied by a concomitant oxidation of NADPH to NADP. The amount of NADPH rema... | US Patent US10172864 (2019) BindingDB Entry DOI: 10.7270/Q2ZK5JQ3 | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H] (411/417 = 99%)† (Homo sapiens (Human)) | BDBM279948 (US10028961, Compound 101 | US10172864, Compound 10...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | n/a | n/a |
Agios Pharmaceuticals, Inc. US Patent | Assay Description In the primary reaction, the reduction of α-KG acid to 2-HG is accompanied by a concomitant oxidation of NADPH to NADP. The amount of NADPH rema... | US Patent US10172864 (2019) BindingDB Entry DOI: 10.7270/Q2ZK5JQ3 | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H] (411/417 = 99%)† (Homo sapiens (Human)) | BDBM279977 (US10028961, Compound 130 | US10172864, Compound 13...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | n/a | n/a |
Agios Pharmaceuticals, Inc. US Patent | Assay Description In the primary reaction, the reduction of α-KG acid to 2-HG is accompanied by a concomitant oxidation of NADPH to NADP. The amount of NADPH rema... | US Patent US10172864 (2019) BindingDB Entry DOI: 10.7270/Q2ZK5JQ3 | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H] (411/417 = 99%)† (Homo sapiens (Human)) | BDBM279977 (US10028961, Compound 130 | US10172864, Compound 13...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | n/a | n/a |
Agios Pharmaceuticals, Inc. US Patent | Assay Description In the primary reaction, the reduction of α-KG acid to 2-HG is accompanied by a concomitant oxidation of NADPH to NADP. The amount of NADPH rema... | US Patent US10172864 (2019) BindingDB Entry DOI: 10.7270/Q2ZK5JQ3 | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H] (411/417 = 99%)† (Homo sapiens (Human)) | BDBM279948 (US10028961, Compound 101 | US10172864, Compound 10...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | n/a | n/a |
Agios Pharmaceuticals, Inc. US Patent | Assay Description In the primary reaction, the reduction of α-KG acid to 2-HG is accompanied by a concomitant oxidation of NADPH to NADP. The amount of NADPH rema... | US Patent US10172864 (2019) BindingDB Entry DOI: 10.7270/Q2ZK5JQ3 | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H] (411/417 = 99%)† (Homo sapiens (Human)) | BDBM279948 (US10028961, Compound 101 | US10172864, Compound 10...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | n/a | n/a |
Agios Pharmaceuticals, Inc. US Patent | Assay Description A test compound is prepared as 10 mM stock in DMSO and diluted to 50× final concentration in DMSO, for a 50 μl reaction mixture. IDH enzyme acti... | US Patent US10172864 (2019) BindingDB Entry DOI: 10.7270/Q2ZK5JQ3 | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132C] (413/414 > 99%)† (Homo sapiens (Human)) | BDBM279948 (US10028961, Compound 101 | US10172864, Compound 10...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | n/a | n/a |
Agios Pharmaceuticals, Inc. US Patent | Assay Description A test compound is prepared as 10 mM stock in DMSO and diluted to 50× final concentration in DMSO, for a 50 μl reaction mixture. IDH enzyme acti... | US Patent US10172864 (2019) BindingDB Entry DOI: 10.7270/Q2ZK5JQ3 | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Isocitrate dehydrogenase [NADP] cytoplasmic [R132C] (413/414 > 99%)† (Homo sapiens (Human)) | BDBM279948 (US10028961, Compound 101 | US10172864, Compound 10...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <50 | n/a | n/a | n/a | n/a | 6.5 | 25 |
Agios Pharmaceuticals, Inc. US Patent | Assay Description In the primary reaction, the reduction of α-KG acid to 2-HG is accompanied by a concomitant oxidation of NADPH to NADP. The amount of NADPH rema... | US Patent US10028961 (2018) BindingDB Entry DOI: 10.7270/Q2ZW1NXM | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) |